Recent Company News

• 06:35 PM ET Apr 10, 2026
  

  Follow-up: Hemab Therapeutics files for Nasdaq IPO of indeterminate size

• 06:31 PM ET Apr 06, 2026
  

  CSL notes U.S. recent section 232 tariffs on pharmaceuticals, expects most of its U.S. product sales will not be subject to tariffs (A$138.93, 0.00)

• 01:49 PM ET Apr 06, 2026
  

  US FTC grants antitrust clearance for CSL's clazakizumab license agreement with Eli Lilly (A$138.93, 0.00)

• 09:04 AM ET Mar 31, 2026
  

  FDA identifies cases of serious liver injury in patients taking Amgen's Tavneos for severe active anti-neutrophil cytoplasmic autoantibody associated vasculitis ($349.00, 0.00)

• 12:01 AM ET Mar 19, 2026
  

  StreetAccount Summary: Australia and New Zealand Stocks reaching new 52-week highs/lows (85 total)

• 11:59 PM ET Mar 16, 2026
  

  StreetAccount Summary: Australia and New Zealand Stocks reaching new 52-week highs/lows (43 total)

• 11:59 PM ET Mar 12, 2026
  

  StreetAccount Summary: Australia and New Zealand Stocks reaching new 52-week highs/lows (67 total)

• 11:55 PM ET Mar 11, 2026
  

  StreetAccount Summary: Australia and New Zealand Stocks reaching new 52-week highs/lows (63 total)

• 09:16 AM ET Mar 10, 2026
  

  StreetAccount Sector Summary - Real Estate Pre Market

• 11:01 AM ET Mar 09, 2026
  

  CSL announces expansion of Illinois plasma therapy manufacturing facility